UNITAID Approves $160M For Investments In Hepatitis C, TB, Malaria

UNITAID has committed $160 million in new grants for investments in hepatitis C, drug-resistant tuberculosis, and malaria chemoprevention. According to a press release, “These innovative investments will reduce prices, overcome market barriers to access for patients, and generate crucial data on new products to speed up their introduction for those most in need.” Grants approved by UNITAID’s executive board this week include grants to Médecins Sans Frontières, Partners in Health, the Malaria Consortium, and Northwestern Global Health Foundation (5/6).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.